Going Skin Deep-er: Dermatologic toxicities of EGF receptor inhibitors in patients with cancer
Cancer therapies have evolved from conventional cytotoxic chemotherapy to targeted drugs that interfere with specific molecules involved in tumour growth. Targeted drugs that inhibit the epidermal growth factor (EGF) receptor have been successfully tested and are in clinical use for various cancers. Dermatologic toxicity is a unique characteristic of this class of drugs.
